Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Payables (2017 - 2025)

Crinetics Pharmaceuticals has reported Payables over the past 9 years, most recently at $41.8 million for Q4 2025.

  • For Q4 2025, Payables rose 94.56% year-over-year to $41.8 million; the TTM value through Dec 2025 reached $41.8 million, up 94.56%, while the annual FY2025 figure was $41.8 million, 94.56% up from the prior year.
  • Payables for Q4 2025 was $41.8 million at Crinetics Pharmaceuticals, up from $33.7 million in the prior quarter.
  • Over five years, Payables peaked at $41.8 million in Q4 2025 and troughed at $3.4 million in Q4 2021.
  • A 5-year average of $15.8 million and a median of $11.0 million in 2022 define the central range for Payables.
  • Biggest five-year swings in Payables: crashed 77.48% in 2024 and later surged 581.8% in 2025.
  • Year by year, Payables stood at $3.4 million in 2021, then soared by 348.6% to $15.4 million in 2022, then skyrocketed by 51.1% to $23.2 million in 2023, then decreased by 7.45% to $21.5 million in 2024, then skyrocketed by 94.56% to $41.8 million in 2025.
  • Business Quant data shows Payables for CRNX at $41.8 million in Q4 2025, $33.7 million in Q3 2025, and $38.1 million in Q2 2025.